Michael A.James Rippee MD
Sports Neurologist, Concussion expert, Medical Director for the Center for Concussion Management at The University of Kansas Health System Associate Professor, Neurology, University Kansas School of Medicine
Join to View Full Profile
3599 Rainbow BlvdKansas City, KS 66103
Dr. Rippee is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Kansas School of MedicineFellowship, Vascular Neurology, 2011 - 2012- University of Kansas School of MedicineResidency, Neurology, 2008 - 2011
University of Missouri Kansas City School of MedicineClass of 2007
Certifications & Licensure
KS State Medical License 2011 - 2025
American Board of Psychiatry and Neurology Neurology- American Board of Psychiatry and Neurology Vascular Neurology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Ghrelin (OXE--103) for Acute Concussion Management Start of enrollment: 2020 Oct 20
Publications & Presentations
PubMed
- The Impact of Cognitive Behavioral Therapy for Insomnia on Neurofilament Light and Phosphorylated Tau in Individuals with a Concussion.Rebecca Ludwig, Michael Rippee, Linda D'Silva, Jeff Radel, Aaron M Eakman
Archives of Clinical Neuropsychology. 2024-11-06 - Evaluating olfactory function and quality of life in patients with traumatic brain injury.Amelia S Lawrence, Rahul Alapati, Sarah F Wagoner, Antonio Bon Nieves, Cole Bird
International Forum of Allergy & Rhinology. 2024-08-01 - 2 citationsAssessing Cognitive Behavioral Therapy for Insomnia to Improve Sleep Outcomes in Individuals With a Concussion: Protocol for a Delayed Randomized Controlled Trial.Rebecca Ludwig, Michael Rippee, Linda J D'Silva, Jeff Radel, Aaron M Eakman
JMIR Research Protocols. 2022-09-23
Press Mentions
Oxeia Announces Positive Interim Results of Phase 2 Trial for oxe103 for the Treatment of ConcussionsAugust 3rd, 2022- Symptoms You May Experience After Getting a COVID-19 VaccineJanuary 5th, 2021
- Oxeia Biopharmaceuticals, Inc. Announces Initiation of Phase 2 Trial for OXE103 for the Treatment of ConcussionsOctober 21st, 2020
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
